Experimental Medicine Study to Measure Immune Checkpoint Receptors PD‐1 and GITR Turnover Rates In Vivo in Humans-Reference-Cited by-同舟云学术

Experimental Medicine Study to Measure Immune Checkpoint Receptors PD‐1 and GITR Turnover Rates In Vivo in Humans

Published:2021-02 Issue:6 Volume:109 Page:1575-1582
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Lassman Michael E.¹,Chappell Derek L.¹,McAvoy Thomas¹,Cheng Amy²,Alwis Dinesh P.³,Pruitt Scott K.⁴,Laterza Omar F.¹,Li Claire³,Stoch Aubrey,Mayawala Kapil³

Affiliation:

1. Translational Molecular Biomarkers Merck & Co., Inc. Kenilworth New Jersey USA

2. Translational Medicine Clinical Operations Merck & Co., Inc. Kenilworth New Jersey USA

3. Quantitative Pharmacology and Pharmacometrics PPDM Merck & Co., Inc. Kenilworth New Jersey USA

4. Oncology Clinical Research Merck & Co., Inc. Kenilworth New Jersey USA

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2129

Reference27 articles.

1. The blockade of immune checkpoints in cancer immunotherapy

2. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance

3. Immuno-oncology drug development forges on despite COVID-19

4. Immune Checkpoint Blockade in Cancer Therapy

5. Redefining the primary objective of phase I oncology trials

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics;Clinical and Experimental Medicine;2023-10-07

2. 2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2023-08

3. Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study;mAbs;2022-12-16

4. Toward Project Optimus for Oncology Precision Medicine: Multi‐Dimensional Dose Optimization Enabled by Quantitative Clinical Pharmacology;Clinical Pharmacology & Therapeutics;2022-10-20